

**John S. Yu, M.D.**

**CURRICULUM VITAE**

**Professional Contact:**

Department of Neurosurgery  
Cedars-Sinai Medical Center  
127 S. San Vicente Blvd, Suite A6600, Los Angeles, CA 90048

**Information:**

Phone: 310-423-0845  
Fax: 310-423-1038  
[yuj@cshs.org](mailto:yuj@cshs.org)

**Education:**

1981-1985	B.A./B.S.	Stanford University, Stanford, CA Université de Paris, Sorbonne, Paris, France
1985-1990	M.S.	Harvard-MIT Division of HST Dept. of Genetics, Cambridge, MA
	M.D.	Harvard Medical School Harvard-MIT Division of Health, Sciences, and Technology, Boston, MA

**Postdoctoral Training:**

Internship and Residencies:

1990-1991	Internship in Surgery Beth Israel Hospital, Boston, MA
1991-1997	Residency in Neurosurgery Massachusetts General Hospital, Boston, MA

Research Fellowships:

1982-1984	Honors Research, Dept. of Biology, Stanford, CA
1984	Summer Intern, Department of Molecular Biology, Genentech, Inc., South San Francisco, CA
1984-1985	Fellow in Immunology, Institut Pasteur, Paris, France Tumor immunology, Dr. Alice Dautry-Varsat
1986	Betty Lea Stone Fellow, American Cancer Society Whitehead Institute, M.I.T., Cambridge, MA Gene therapy, Dr. Richard Mulligan
1988-1989	Neuroscience Fellow, National Institute of Mental Health, Neuroimmunology Unit, Massachusetts General Hospital, Boston, MA MS neuroimmunology, Dr. Stephen Hauser
1993-1995	Culpeper Scholar, Molecular Neurogenetics Unit, Massachusetts General Hospital, Boston, MA Gene therapy, Dr. Xandra Breakefield

<b>Licensure:</b>	1990-1998	Massachusetts State Medical License, 152067
	1997-Present	California State Medical License, G084283
<b>Board Certification:</b>	1990	Diplomat, National Board of Medical Examiners
	2001	Diplomat, American Board of Neurological Surgery
<b>Professional Experience:</b>	2019-	Clinical Chief, Department of Neurosurgery Cedars-Sinai Medical Center
	2011-Present	Director, Brain Tumor Program (Research) Cedars-Sinai Medical Center
	2009-Present	Vice-Chairman, Department of Neurosurgery Cedars-Sinai Medical Center
	2008-Present	Professor of Neurosurgery Cedars-Sinai Medical Center
	2008-Present	Medical Director, Brain Tumor Center (Clinical) Cedars-Sinai Medical Center
	2006- Present	Director, Surgical Neuro-oncology Director, Gamma Knife Cedars-Sinai Department of Neurosurgery
	1998-Present	Director, Comprehensive Brain Tumor Fellowship Cedars-Sinai Medical Center
	1998-2006	Co-Director, Comprehensive Brain Tumor Program Cedars-Sinai Medical Center Maxine Dunitz Neurosurgical Institute
	1998-2001	Assistant Clinical Professor Department of Neurological Surgery University of California, Irvine
	1997-1998	Instructor in Surgery, Harvard Medical School Assistant in Neurosurgery, Massachusetts General Hospital, Boston, MA
<b>Professional Activities:</b>	2000-Present	American Association of Neurological Surgeons
	2000-Present	Society for Neuro-Oncology
	2001-Present	American Association for the Advancement of Science
	2001-Present	Ad hoc reviewer: Cancer Research, The Lancet, Clinical Cancer Research, Stem Cell, Oncogene, Molecular Therapy, Journal of Neuro-Oncology, Proceedings of the National Academy of Sciences, Journal of Neurosurgery, Cancer, Cancer Letters, Gene Therapy, Human Gene Therapy, Lab Invest.
	2001-Present	Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurological Surgeons
	2005-Present	International Society for the Biological Therapy of Cancer
	2006-Present	International Society for Stem Cell Research
	2006-Present	Editor, Current Stem Cell Research and Therapy
	2006-Present	Korean American Neurosurgical Society – Director
	2007-2009	American Board of Neurological Surgery – Written Examination Committee
	2007-Present	Renaissance Weekend Speaker

	2010-Present	Editor, World Journal of Stem Cells
	2011-2013	Society for Brain Mapping and Therapeutics– Director
<b>CSMC Professional Activities:</b>	2002-Present	Faculty Academic Advisory Council, Cedars-Sinai Medical Center
	2002-Present	Facilitator, Quality Assurance (Neurosurgery), Cedars-Sinai Medical Center
	2003	O.R. Advisory Committee, Cedars-Sinai Medical Center
	1997-Present	Brain Tumor Board, Cedars-Sinai Medical Center
	1997-Present	SAE Review Committee Meeting, Cedars-Sinai Medical Center
<b>Other Professional Activities:</b>	2000	Brain Tumor Progress Review Group (NCI/NINDS) Roundtable Participant
<b>UCLA &amp; other affiliated institutions</b>	2000-Present	Cancer Committee
	2003	PPG site visit for Parent Subcommittee D (Clinical Research Studies), National Cancer Institute
	2003	Ad hoc reviewer for Research Programs Review Branch, National Cancer Institute
	2003	Congressionally Directed Medical Research Programs Peer Review
	2003	Institutional Review Board
	2004	Program Project Cluster Review for Parent Subcommittee C and D, National Cancer Institute
	2005	Special Emphasis Panel, Molecular, Cellular and Developmental Neurosciences IRG
	2005	Head, Subgroup on Research and Tech Transfer, Neuroscience Center of Excellence Task Force
	2005	Member, Search Committee for Chairman of the Department of Pathology
	2006-Present	Neurosurgery Performance Improvement Committee
	2006-2009	Pioneer Award Nomination Committee
	2007-2014	Directors of Centers of Excellence
	2008	Clinical Studies Special Emphasis Panel D
	2009	Cancer Center Protocol Review and Monitoring Committee
	2009	Cancer Center Planning Committee
	2009	Rehabilitative Medicine Planning Committee
	2009-Present	SAE, Safety Oversight Committee
	2010	Cancer Center Grant Site Review of University of Pittsburgh Cancer Institute /NCI
	2010-Present	Crimson Physician Performance Advisor
	2011-Present	Cancer Institute Phase I Trials Committee
	2012-Present	Developmental Therapeutics Study Section (DT) Standing member
<b>Honors and Special Awards:</b>	1985	Graduated Stanford University with Distinction, Graduated with Honors in the Biological Sciences, Phi Beta Kappa -Stanford University Chapter

1995	Preuss Resident Award Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurological Surgeons
1996	Academy Award American Academy of Neurological Surgery
2000	Joint Section on Tumors Young Investigator Award American Association of Neurological Surgeons and Congress of Neurological Surgeons
2001	National Brain Tumor Foundation Award Joint Section on Tumors (American Association of Neurological Surgeons and Congress of Neurological Surgeons)
2002-Present	Marquis Who's Who in Medicine
2003-Present	Marquis Who's Who in Science and Engineering
2005	Mahaley Clinical Research Award Congress of Neurological Surgeons
2005-Present	America's Top Doctors (Castle Connolly Medical, Ltd.)
2005-Present	America's Top Cancer Specialists (Castle Connolly Medical, Ltd.)
2007-Present	Southern California Super Doctors, Los Angeles Magazine
2007	IEEE Outstanding Speaker Engineering in Medicine & Biology
2008-Present	Marquis Who's Who in America
2009-Present	Marquis Who's Who in the World
2011	Career Achievement Award Korean-American Medical Association

**Research Grants and  
Fellowships Received:**

**American Cancer Society  
Betty Lea Stone Fellowship**

Major goals: To develop gene transfer strategies based on a chimeric EBV  
and retrovirus based vector.

Dates of Approval: 07/01/86 – 9/30/86

Mentor: Dr. Richard Mulligan

Role: Fellow

**National Institute of Mental Health  
Neuroscience Fellowship**

Major goals: To determine the genetic etiology of familial multiple sclerosis.

Dates of Approval: 07/01/88 – 06/30/89

Mentor: Dr. Stephen L. Hauser

Role: Fellow

**Charles E. Culpeper Foundation**

GM-CSF vaccination for malignant glioma

Major goals: To develop vaccination therapies in a murine malignant glioma  
model based on peripheral tumor production of cytokines.

Dates of Approval: 07/01/93 – 09/30/95

Role: Principal Investigator

Total Grant Support / Percent Effort: \$187,500 / 100%

**National Institutes of Health (NIH)**

Project Number (Principal Investigator): K23 NS02232-01 (Yu, J)

Title of Project (and /or Subject): *Active Immunotherapy for Glioblastoma*

Summary: The purpose of this project is to advance promising cell based and gene based immunotherapy of malignant gliomas from preliminary animal studies to phase I/II clinical trials.

Dates of Approval: 09/30/00 – 08/31/05

Role: Principal Investigator

Total Grant Support / Percent Effort: \$878,865 / 75 %

**National Brain Tumor Foundation**

Major goals: To develop a randomized Phase II Trial of Dendritic Cell Immunotherapy for Patients with Glioblastoma. Antigen specific cytotoxic T cell response and intracranial T cell infiltration were endpoints.

Dates of Approval: 07/01/01 – 06/30/02

Role: Principal Investigator

Total Grant Support / Percent Effort: \$62,500 / 5%

**National Institutes of Health (NIH)**

Project Number (Principal Investigator): R21 NS047298 01 (Lowenstein, P)

Title of Project (and/or Subproject): *Gene Therapy for Glioma*

Summary: The long-term goal of this project is to develop a novel gene therapy approach for the treatment of glioblastoma tumors, using high-capacity adenoviral vectors, with novel high expressing promoters.

Dates of Approval: 12/01/03 – 11/30/05

Role: Co-Investigator

Total Grant Support /Percent Effort: \$390,000 / 5%

**National Institutes of Health (NIH)**

Project Number: 2 R01 NS048959-01

Title of Project (and /or Subject): *Bone marrow-derived neural stem cell therapy for glioma*

Summary: The purpose of this project is to define the mechanisms of neural stem cell proliferation and differentiation from bone marrow cells and to translate their marked tropism for brain tumor therapy.

Dates of Approved/Proposed Project: 9/1/04 – 8/31/2016

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$1,965,356 / 20% Present cycle

**National Institutes of Health (NIH)**

Project Number: 1 R01 NS048959-01S1

Title of Project (and /or Subject): Minority Faculty Development Grant  
for *Bone marrow-derived neural stem cell therapy for glioma*

Summary: This supplemental Minority Faculty Mentoring Grant is for the mentorship of Dr. Dwain Morris-Irvin to develop into an independent investigator through intensive training within the RO1 granting mechanism.

Dates of Approved/Proposed Project: 9/30/04 – 8/31/2011

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$ 666,656/ 5%

**Musella Foundation**

Title of Project (and /or Subject): *Dendritic Cell Immunotherapy for Brainstem Glioma*

Summary: The purpose of this project is to study the effect of dendritic cells loaded with tumor associated peptides on patients with brainstem glioma.

Dates of Approved/Proposed Project: 9/01/05 – 10/1/2007

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$100,000 / 1%

**National Institutes of Health (NIH)**

Project Number (Principal Investigator): R21 NS048879-01 (Yu, J)

Title of Project (and /or Subject): *Human bone marrow-derived neural stem cell therapy*

Dates of Approved/Proposed Project: 10/01/05 – 9/20/2007

Summary: The purpose of this project is to translate the use of human bone marrow derived neural stem cell therapy for the treatment of patients with glioblastoma

Role: Principal Investigator

Total Grant Support / Percent Effort: \$390,000 / 20%

**Cedars Sinai Research Institute**

Project Number (Principal Investigator): 216173 (Yu, J)

Title of Project (and /or Subject): *Neural stem targeting tumor stem cells*

Dates of Approved/Proposed Project: 10/01/05 – 9/30/2007

Summary: The purpose of this project is to study the tropism of neural stem cells toward cancer stem cells

Role: Principal Investigator

Total Grant Support / Percent Effort: \$37,500 / 5%

**Neches Foundation**

Title of Project (and /or Subject): *Dendritic Cell Immunotherapy for Anaplastic Oligodendroglioma*

Dates of Approved/Proposed Project: 9/01/06 – 8/30/2007

Summary: The purpose of this project is to study the effect of dendritic cells loaded with tumor associated peptides on patients with anaplastic oligodendroglioma

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$100,000 / 1%

**MGI Pharma**

Title of Project (and /or Subject): *Dendritic Cell Immunotherapy and Gliadel for Glioblastoma*

Summary: The purpose of this project is to study the synergy of intracranial BCNU chemotherapy with dendritic cell immunotherapy

Dates of Approved/Proposed Project: 9/01/06 – 8/31/2008

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$375,000 / 2%

**Oncolytics, Inc.**

Title of Project (and /or Subject): *Reolysin007 –Phase I/II Trial of Reoviral Oncolytic Therapy for Malignant Glioma*

Summary: The purpose of this project is find the maximal tolerated dose of intratumoral oncolytic virus infusion in the treatment of patients with recurrent malignant glioma.

Dates of Approved/Proposed Project: 3/01/07 – 8/30/2008

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$924,281 / 5%

**Douglas Fieger Foundation**

Title of Project (and /or Subject): *Dendritic Cell Immunotherapy for Metastatic Brain Tumors*

Summary: The purpose of this project is to study the effect of dendritic cells loaded with tumor associated peptides on patients with metastatic brain tumors.

Dates of Approved/Proposed Project: 2/1/08 – 1/31/2009

Principal Investigator: Yu, JS

Annual Direct Costs / Percent Effort: \$100,000 / 1%

**National Institutes of Health (NIH)**

Project Number: R21 CA131999-01

Title of Project (and /or Subject): Targeting cancer stem cells for brain tumor therapy

Summary: The purpose of this project is to define the mechanisms tropism of neural stem cells toward cancer stem cells to exploit this property as a means of specifically targeting cancer stem cells for oncolytic and immunologic therapies.

Dates of Approved/Proposed Project: 3/01/08 – 2/28/2010

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$935,000 / 20%

**Lucas Goldbaum Foundation**

Title of Project (and /or Subject): *HLA-A1-specific Cancer Stem Cell Vaccine*

Summary: The purpose of this project is to study the effect of a peptide vaccine targeting CD133 positive cancer stem cells

Dates of Approved/Proposed Project: 2/01/09 – 1/31/2010

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$270,000 / 1%

**MacFarlane Foundation**

Title of Project (and /or Subject): *Stem Cell Therapies for Cancer and*

Summary: The purpose of this project is to develop stem cell therapies for brain cancers and neurodegenerative disorders

*Neurodegenerative Disorders*

Dates of Approved/Proposed Project: 4/01/2010 – 3/31/2011

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$200,000 / 1%

**National Institutes of Health (NIH)**

Project Number: R56 NS048959-01

Title of Project (and /or Subject): *Bone marrow-derived neural stem cell therapy for glioma*

Summary: This is merit bridge grant for meritorious R01 research for competitive renewal. The goal of the studies is to determine mechanisms underlying tropism of neural stem cells, bone marrow derived neural stem cells, and cancer stem cells.

Dates of Approved/Proposed Project: 4/01/2010 – 3/31/2011

Principal Investigator: Yu, JS

Total Grant Support / Percent Effort: \$402,000 / 20%

**California Institute for Regenerative Medicine (CIRM)**

Title of Project (and /or Subject): *Stem Cell Therapies for Neurological Disorders*

Summary: The purpose of this project is to organize an annual international symposium highlighting the barriers to translating stem cell therapies for neurological disorders.

Dates of Approved/Proposed Project: 5/1/2011 – 4/30/2012

Principal Investigator: Yu, JS

Annual Direct Costs / Percent Effort: \$17,000 / 1%

**Martz Translational Breast Cancer Discovery Fund**

Title of Project (and /or Subject): *Immunological targeting of CD133 in metastatic breast carcinoma patients*

Summary: The purpose of this project is to translate a dendritic cell vaccine targeting CD133 into an investigator initiated trial for breast carcinoma patients.

Dates of Approved/Proposed Project: 1/1/2012 – 12/31/2016

Principal Investigator: Yu, JS

Total Direct Costs / Percent Effort: \$300,000 / 10%

**FasterCures**

Title of Project (and /or Subject): *Immunological targeting of cancer stem cells in glioblastoma patients*

Summary: The purpose of this project is to translate a dendritic cell vaccine targeting cancer stem cells into investigator initiated trial for glioblastoma patients

Dates of Approved/Proposed Project: 6/1/2012 – 5/31/2017

Principal Investigator: Yu, JS

Total Direct Costs / Percent Effort: \$4,098,360 / 8%

**Department of Defense**

Project Number (Principal Investigator) BC142354 (Medani-Kauwe, LK)

Title of Project (and /or Subject): *Nanobiologic Targeting of Metastatic Breast Tumors*

Summary: The purpose of this project is to study the effect of nanoparticles consisting of corrole and chemotherapeutics targeting HER3 on breast cancers metastatic to the brain.

Dates of Approved/Proposed Project: 1/1/2016 – 12/31/2018

Role: Co-Investigator



Annual Direct Costs / Percent Effort: \$233,000 / 2%

**California Institute for Regenerative Medicine (CIRM)**

Project Number: CTS1-08280

Title of Project (and /or Subject): A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

Summary: The purpose of this project is support the phase 3 clinical trial of an autologous dendritic cell vaccine that targets cancer stem cell antigen in patients with newly diagnosed glioblastoma. This trial will enroll 420 patients through the Alliance in the United States, the EORTC in Europe, and the Brain Tumor Consortium in Canada.

Dates of Approved/Proposed Project: 10/1/2016 – 9/30/2021

Role: Chief Scientific Officer

Total Direct Costs / Percent Effort: \$19,900,000/ 10%

**Toscano Lung Cancer Discovery Fund**

Title of Project (and /or Subject): *Immunological targeting of CD133 in NSCLC patients*

Summary: The purpose of this project is to translate a dendritic cell vaccine targeting CD133 into an investigator initiated trial for breast carcinoma patients.

Dates of Approved/Proposed Project: 1/1/2017 – 12/31/2018

Principal Investigator: Yu, JS

Total Direct Costs / Percent Effort: \$400,000 / 10%

**Patents:**

Herpes Simplex Virus Type (HSV-1) – Derived Vector for Selectively Inhibiting Malignant Cells and for Expressing Desired Traits in Malignant and Non-Malignant Mammalian Cells (patent issued January 4, 2005; #6,838,279; patent #7,129,034, issued October 31, 2006)  
Method for Delivering a Biological Compound Using Neural Progenitor Cells Derived from Whole Bone Marrow (patent issued March 17, 2009)

Neural progenitor cells derived from whole bone marrow (patent ##7,504,100, issued January 17, 2012; #8,097,256)

Cancer Vaccines and Vaccination Methods (patent #8,097,256, issued January 17, 2012)

Cancer Stem Cell Antigen Vaccine and Methods (patent #8,129,184, issued March 6, 2012)

Use of Cox-2 inhibitor to prevent T-cell anergy induced by dendritic cell therapy (patent issued March 19, 2012; EP Application #04809859.4)  
Antioxidant nanosphere comprising of [1,2]-dithiolane moieties (patent #8,318,795, issued November 27, 2012)

Nanometer-sized prodrugs of NSAIDs (patent #8,603,531, issued December 10, 2013)

Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof (patent #8,697,743, issued April 15, 2014)

Cancer stem cell antigen vaccines and methods (patent #9,023,338, issued May 5, 2015)

Systems and methods for prognosticating brain tumors  
(Grant US9915659B2 issued May 13, 2018)

## Research Projects and

### Research Focus or Interest: **FDA-Approved Investigational New Drugs:**

BB-IND 7462 -“Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells Cultured with Granulocyte Macrophage Colony Stimulating Factor (Immunex) and Interleukin-4 (R&D Systems) Pulsed with Tumor Specific Peptides” Sponsor: J.S. Yu Status: Active

BB-IND 7774 - “Autologous Dendritic Cells Cultured Ex Vivo with Granulocyte Macrophage colony Stimulating Factor (Immunex) and Interleukin-4 (R&D Systems), Pulsed with Autologous Tumor Cell Lysate and Keyhole Hemocyanin (Calbiochem)” Sponsor: J.S. Yu Status: Active

BB-IND 12891 - “Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Matured Ex Vivo with Granulocyte Macrophage colony Stimulating Factor and Interleukin-4, Cultured with Mature Tumor Lysate and Keyhole Limpet Hemocyanin; Followed with Chemotherapy” Sponsor: J.S. Yu Status: Active

BB-IND12272 - “Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Expanded with Interleukin-4, Granulocyte-Macrophage Colony-Stimulating Factor, and Tumor Necrosis Factor-alpha; Pulsed with Tumor Antigens” Sponsor: J.S. Yu, transferred to Immunocellular Therapeutics, Ltd. Status: Active

BB-IND 11033 - “Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells Cultured Ex Vivo with Granulocyte Macrophage colony Stimulating Factor (Immunex) and Interleukin-4 (R&D Systems), Intracranial, with or without Radiotherapy” Sponsor: J.S. Yu (Transferred to Immunocellular Therapeutics, Ltd.); Status: Active

BB- IND 15145 - “CD133 targeting Dendritic Cell Vaccine” Sponsor: J.S. Yu and J. Rudnick; Status: Active July 12, 2012

BB-IND - “Autologous Bone Marrow Derived Neural Progenitor Cells Transduced Ex Vivo with Adenoviral Vector Encoding IL-23” Sponsor: J.S. Yu; Status: Pre-IND conference

### **IRB-approved Investigator-initiated Clinical Trials:**

6/1/2005–5/31/2006	IRB 3440 - Laser Fluorescence for Brain Tumors. PI: A. Mamelak (Role: Co-investigator)
12/2006–12/2007	IRB 7917 - A Phase II Trial of Dendritic Cells Pulsed with Tumor Lysate Followed by Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme. PI: J.S. Yu
2/1/2007–1/31/2008	IRB 4354 - A phase I study of Pioglitazone and Isotretinoin for malignant gliomas. PI: R. Chu (Role: Co-investigator)
2/1/2007–1/31/2008	IRB 4130 - A phase I trial of intracranial immunotherapy for malignant brain tumors. PI: J.S. Yu
11/1/2007–9/30/2008	IRB 4290 phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma multiforme. PI: S Phuphanich (Role: Co-investigator)
5/1/2009–4/30/2010	IRB 8863 -131 I-TM-601 in Patients with Recurrent High Grade Glioma. PI: A. Mamelak (Role: Co-investigator)
11/1/2010–10/31/2011	IRB 3368 - A phase II trial of tumor lysate-pulsed dendritic cell immunotherapy for patients with atypical or malignant, primary or metastatic brain tumors of the central nervous system. PI: J.S. Yu
12/1/2010–11/30/2011	IRB 13574 - A Phase I/II trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN for patients with recurrent Malignant Gliomas. PI: J.S. Yu
5/2011–4/2012	IRB 6657 - A Phase I Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients with Brainstem Glioma and Glioblastoma. PI: S Phuphanich (Immunocellular Therapeutics/ J.S. Yu Sponsored)
4/1/2012–2013	IRB 9789 - A Phase I Trial of Surgical Resection with Gliadel Wafer Placement Followed by Vaccination with Dendritic Cells Pulsed with Tumor Lysate for Patients with Malignant Glioma. PI: J.S. Yu
3/1/2017–2/28/2018	IRB 3646 - The Brain and CNS Tissue Registry. PI: J.S. Yu

- 3/1/2017–2/28/2019 IRB 8922 - Tumor Specimens and Cell Cultures. PI: J.S. Yu
- 9/1/2017–8/31/2018 IRB 35902 - A Phase I study of Ad-RTS-hIL-12, and inducible adenoviral vector engineered to express hIL-12 in the presence of the activator ligand Veledimex in Subjects with Recurrent or progressive glioblastoma or grade III malignant glioma. PI: J.S. Yu
- 12/1/2017–11/30/2018 IRB 9225 - Screening protocol for vaccine trials. PI: J.S. Yu
- IRB 2178 - A phase I trial of MHC-I associated peptide pulsed dendritic cell vaccination for patients with malignant glioma. PI: J.S. Yu
- IRB 3320 - A phase I trial of allogeneic GM-CSF secreting vaccine for treatment of glioblastoma. PI: J.S. Yu
- IRB 14299 - Neural Stem Cells For Brain Tumor Therapy. PI: J.S. Yu

**Invited Lectures and Presentations:**

Visiting Lecturer/Professor, “Active Immunotherapy for brain tumors”, Pediatric Brain Tumor Symposium, University of Minnesota, Minneapolis, Minnesota, February 2001

Invited Speaker, “Dendritic cell vaccines for glioblastoma”, Preuss Foundation Seminar on Vaccine Therapy for Malignant Primary Brain Tumors, Dartmouth, New Hampshire, June 2002

Visiting Lecturer/Professor, “Neural Stem Cell Therapies for Neurodegenerative Disorders”, Pediatric Neurology Symposium, Northwestern University, Chicago, Illinois, November 2002

Visiting Lecturer/Professor, “Dendritic cell vaccination for brain tumors”, Neurosurgery Grand Rounds, Columbia College of Physicians and Surgeons, New York, New York, July, 2003

Invited Lecturer, “Active Immunotherapy for Glioblastoma”, University of Pittsburg Cancer Institute, September 25, 2003

Invited Speaker, “Neural Stem Cell Therapies for Gliomas”, Symposium on Stem Cells and Gliomas, Biennial Meeting of the Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurological Surgeons, San Francisco, CA, October 2004

Visiting Lecturer/Professor, “Bone marrow derived neural stem cells”  
Biochemistry Grand Rounds, Weill School of Medicine, New York, New  
York, February 2005

Invited Speaker, “Basic Concepts in Antigen Presentation in the Central  
Nervous System” Aspen Symposium on Brain Tumor Immunotherapy, Given  
Institute, Aspen, Colorado. August 8 – 9, 2005

Visiting Lecturer/Professor, “Stem cell therapies for neurorestoration”, Brain  
Tumor Symposium, Catholic University, Seoul, Korea, November, 2005

Invited Speaker, "CNS Tumor Stem Cells - An Eye towards the Clinic",  
Harvard Medical School Frye Halloran Symposium 2005, Boston,  
Massachusetts, November 17-18, 2005

Invited Speaker, “Neural Stem Cell Therapies for Gliomas”, Neurosurgery  
Grand Rounds, University of Southern California, Los Angeles, CA,  
November 2006

Visiting Lecturer/Professor, “Neural Stem Cell Therapies”, First International  
Collaborative Symposium on Stem Cell Research, Seoul, Korea, December  
2006

Visiting Lecturer/Professor, “Stem cells in Gliomagenesis and therapy”,  
Pochun University, Seoul, Korea, December 2006

Invited Speaker, “Stem cells in glioma genesis and treatment”, Symposium on  
Brain Tumor Advances, 97<sup>th</sup> Annual American Association of Cancer  
Research (AACR) Meeting, Washington, D.C. , April 3, 2006

Invited Speaker, "Stem Cell Treatment of Brain Tumors and Cancers",  
Buenaventura IEEE Engineering in Medicine & Biology, Thousand Oaks,  
California, January 31, 2007

Invited Speaker, “Surgical therapy of gliomas”, Recent Advances in Glioma  
Research and Therapy, Brigham and Women’s Hospital, Harvard Medical  
School, Boston, Massachusetts, October 2007

Invited Speaker, “Novel therapies for gliomas”, Neurology Grand Rounds,  
University of Southern California, Los Angeles, CA, March 2008

Invited Speaker, “Neural stem cell therapy for ALS and spinal cord injury”,  
Korean American Spine Society, Lahaina, HI,  
July 18, 2008

Visiting Professor, “Stem cells in glioma genesis and treatment” Stanford  
University Department of Neurosurgery, Stanford, CA.  
September 12, 2008

Invited Speaker, “Stem Cells in Gliomagenesis”, Mayo-Luther Forum on  
Hematopoietic and Stem Cells, Mayo Clinic, Rochester, MN, July 17, 2009

Visiting Professor, “Stem cells and Cancer”, Department of Neurosurgery, Wake Forest University School of Medicine, Winston-Salem, NC, January 18, 2010

Invited Speaker, “New Hope for Immunotherapy for Brain Tumors”, Annual Meeting of the American Association for Cancer Research, Washington, DC, April 19, 2010

Invited Speaker, “Immunotherapy for glioblastoma stem cells”, Annual Meeting of the American Association of Neurological Surgeons, Philadelphia, PA, May 4, 2010

Invited speaker, “Immune Targeting of Cancer Stem Cells” 7th Annual Stem Cell Research & Therapeutics Conference, Boston, MA, May 26- 27, 2011

Invited Keynote Speaker “Cancer Stem Cells and The Art of War”, Annual Meeting of the Korean American Medical Association, Seoul Korea, August 5, 2011

Invited Speaker, “Targeting Cancer Stem Cells”, 5<sup>th</sup> Advances in Stem Cell Discovery and Development, San Diego, CA, Oct. 19, 2011

Invited Speaker, “Current State of the Art: Vaccine Development in the Treatment of GBM.” Annual Meeting of the Society for Neuro-Oncology, Anaheim, CA, Nov. 19, 2011

Invited Speaker, “Cancer Vaccines and Cancer Immunotherapy & Immunomodulation” The New York Academy of Sciences, New York, NY, May 15, 2012

Invited Speaker, “Brain Mapping Day,” United States Congress, Washington, D.C, May 24, 2012

Invited Professor, “Course on Brain Tumors,” Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y, July 19-21, 2012

Invited Speaker, Arrowhead’s second annual conference on cancer immunotherapy, Washington, D.C., April 4, 2013

Invited Speaker, 12th International Symposium on Dendritic Cells (DC2012), Seoul, Korea, October 12, 2013

New York Academy of Sciences invited lecture (Second invitation), Clinical Trials of Dendritic Cell Therapies for Cancer' symposium, New York, New York, October, 2013

Invited Speaker, Sunrise Session on Vaccine Therapy, Society for Neuro-Oncology, Miami, FL, November 16, 2014

Invited Speaker and Chair, Nanomedicine Session, Annual Meeting of the Society for Brain Mapping and Therapeutics, March 16, 2015

Visiting Professor, Department of Neurosurgery, University of Texas, Houston, Texas, April, 2015

Invited Speaker, Shenjing Medical College, Shenyang China  
March, 2018

Visiting Professor, Department of Neurosurgery, Konkuk University,  
Seoul, Korea, March 2018

**CSMC Teaching Activities  
and/or Other off-campus  
teaching:**

1997 – Present Journal Club, Cedars-Sinai Medical Center  
1997 – Present Academic Clinic, Cedars-Sinai Medical Center

**Graduate Students Trained:**

2010 Daniel Nwachokor  
Washington Gifted Scholar in Neuroscience  
2011 Robert Reed  
Washington Gifted Scholar in Neuroscience  
2011 Isaac Asare Bediako  
2011 Felix Alonso-Valenteen  
2013-Present Mecca Madany  
2014-Present Tom Thomas  
2017-Present Justin Michael

**Fellows Trained:**

1999-2001 Ken Samoto, M.D.: Associate Professor of Neurosurgery,  
Jikkei University, Tokyo, Japan  
1999-2002 Yunhui Lui, M.D.: Professor of Neurosurgery,  
China Medical University, Shenyang, China  
2001-2003 Yasuharu Akasaki, M.D., Ph.D., Associate Professor of Neurosurgery,  
Jikkei University, Tokyo, Japan  
2001-2003 Peter Kabos, M.D., Ph.D., Fellow in Hematology-Oncology,  
University of Southern California  
2001-2003 Moneeb Ehtesham, M.D., Assistant Professor in Neurosurgery,  
Vanderbilt University  
2002-2003 Hengli Tin, Director and Professor of Neurosurgery, Shanghai 6<sup>th</sup>  
Hospital, Shanghai, China  
2003-2004 Lizhi Lu, Professor of Animal Science, Zheang Academy of  
Agricultural Science, Hangzhou, China  
2003-2005 Patrizia Tunici, Ph.D, Asst. Professor, University of Milan  
2003-2007 Dwain Morris-Irvin, Ph.D., Research Scientist,  
Cedars-Sinai Medical Center  
2006-2007 Joshua Kouri, M.D. (Department of Neurosurgery Surgical  
Oncology Fellow)  
2007-2008 Kyung Gi Cho, M.D., DMSc, Professor of Neurosurgery, Ajou  
University School of Medicine, Suwon, Korea  
2004-2008 Gentao Liu, Ph.D., Senior Research Scientist,

2008-2010	Glaxo Smith Kline, Shanghai, China Anna Milanesi, Ph.D., Endocrine Fellow, Cedars-Sinai Medical Center
2012-2015	Amano Takayuki
2018-2019	J. Manuel Sarmiento

## BIBLIOGRAPHY/PUBLICATIONS:

### RESEARCH PAPERS:

#### Research Papers (Peer-Reviewed)

##### A. Research Papers – Peer Reviewed

1. Dautry F, Weil D, **Yu JS**, Dautry-Varsat A. Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. *J Biol Chem* 263: 17615-7620, 1988.
2. **Yu JS**, Hayashi T, Seboun E, Sklar RM, Doolittle TH, Hauser SL. Fos RNA accumulation in multiple sclerosis white matter *J Neurol Sci* 103:209-215, 1991.
3. **Yu JS**, Moore MR, Kupsky WJ, Scott RM. Intracranial melanotic tumor of infancy: Two case reports *Surg Neurol* 37:123-129, 1992.
4. **Yu JS**, Pandey JP, Massacesi L, Lincoln R, Usuku K, Seboun E, Hauser SL. Segregation of immunoglobulin heavy chain constant region genes in multiple sclerosis sibling pairs. *J Neuroimmunol* 42:113-116, 1993.
5. **Yu JS**, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma with genetically engineered interleukin-4 secreting cells *Cancer Res* 53:3125-3128, 1993.
6. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, **Yu JS**, Pechan PA, Paulus W, Chiocca EA, Breakefield XO. Gene therapy for brain tumors. *Brain Pathol* 5:345-381, 1995.
7. **Yu JS**, Short MP, Schumacher J, Chapman PH, Harsh GR, IV. Intramedullary hemorrhage of spinal cord hemangioblastoma. Report of two cases. *J Neurosurg* 81:639-40, 1996.
8. **Yu JS**, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA. Retroviral delivery and tetracycline-dependent expression of IL-1 $\beta$ -converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. *Cancer Res* 56:5423-5427, 1996.
9. Kim DH, Gutin PH, Noble LJ, Nathan D, **Yu JS**, Nockels RP. Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury. *Neuroreport* 7:2221-2225, 1996.
10. **Yu JS**, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. *Human Gene Therapy* 8(9), 1997.
11. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, **Yu JS**. Vaccination for experimental gliomas using granulocyte-macrophage colony-stimulating factor-transduced glioma cells. *Cancer Gene Therapy* 4:345-352, 1997.
12. **Yu JS**. Gene therapy for brain tumors. *Drug News and Perspectives* 10(6), 10:528-534, 1997.



13. Zeltzer PM, **Yu JS**, Black KL. Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application. *Childs Nerv Syst* 15:514-528, 1999.
14. **Yu JS**, Yong WH, Wilson D, Black KL. Glioblastoma induction after radiosurgery for meningioma. *Lancet* 356:1576-1577, 2000.
15. Schievink WS, Thompson RC, Levine S, **Yu JS**. Superficial Temporal Artery to Middle Cerebral Artery Bypass and External Carotid Reconstruction for Carotid Restenosis Following Angioplasty and Stent Placement. *Mayo Clin Proc* 75:1087-1090, 2000.
16. **Yu JS**, Wheeler CJ, Zeltzer PM, Finger D, Lee PK, Pins R, Yong WH, Thompson RC, Riedinger M, Zhang W, Black KL. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. *Cancer Res* 61:842-847, 2001. (Selected as cover illustration)
17. Samato K, Ehtesham M, Perng GC, Hashizume K, Wechsler SL, Nesburn AB, Black KL, **Yu JS**. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation. *Cancer Gene Therapy* 8(4):269-277, 2001.
18. Samato K, Ehtesham M, Perng GC, Hashizume K, Wechsler SL, Nesburn AB, Black KL, **Yu JS**. A herpes simplex virus type 1 mutant with gamma34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. *Neurosurgery* 50(3):599-605, 2002.
19. Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villareal LP, Black KL, **Yu JS**. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. *Cancer Gene Ther* 9:9-15, 2002.
20. Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villareal LP, Black KL, **Yu JS**. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor alpha gene transfer. *Cancer Gene Therapy* 9(11):925-934, 2002.
21. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, **Yu JS**. The use of interleukin 12 secreting neural stem cells for the treatment of intracranial glioma. *Cancer Research* 62:5657-5663, 2002. (Selected as cover illustration)
22. Kabos P, Ehtesham M, Kabosova A, Black KL, **Yu JS**. Neural progenitors from adult bone marrow. *Experimental Neurology* 178(2):288-293, 2002. (Selected as cover illustration)
23. Ehtesham M, Kabos P, Gutierrez MAR, Chung NHC, Griffith TS, Black KL, **Yu JS**. Induction of glioblastoma apoptosis using neural stem cell mediated delivery of tumor necrosis factor-related apoptosis inducing ligand. *Cancer Research* 62(24):7170-7174, 2002.
24. Ehtesham M, Kabos P, Gutierrez MAR, Samoto K, Black KL, **Yu JS**. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma. *Journal of Immunotherapy* 26:107-116, 2003.
25. Ehtesham M, Kabos P, Yong WH, Schievink WS, Black KL, **Yu JS**. Development of an intracranial ependymoma at the site of a pre-existing cavernous malformation. *Surgical Neurology* 60:80-2, 2003.
26. **Yu JS**, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ. Intratumoral T-cell subsets and endothelial Fas ligand expression in brain tumors. *J Neurooncol* 64:55-61, 2003.
27. Liu G, Khong HT, Wheeler CJ, **Yu JS**, Black KL, Ying H. Molecular and functional analysis of tyrosine related protein (TRP)-2 as cytotoxic T lymphocyte target in malignant glioma. *J Immunother* 26:301-12, 2003.
28. Kabos P, Ehtesham M, Black KL, **Yu JS**. Neural stem cells as delivery vehicles. *Expert Opinion Biol Ther* 3:759-70, 2003.
29. Wheeler CJ, Black KL, Liu G, Ying H, **Yu JS**, Zhang W, Lee PK. Thymic CD8+ T cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality. *J Immunology* 171(9):4927-33, 2003.

30. Ehtesham M, Kabos P, Black KL, **Yu JS**. Use of neural stem cells as therapeutic vehicles for the treatment of malignant glioma. *Expert Rev of Neurotherapeutics* 3(6):883-895, Nov 2003.
31. Ehtesham M, Kabos P, Black KL, **Yu JS**. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. *Cancer Control* 11(3):192-195, 2004.
32. Liu G, Ng H, Akasaki Y, Yuan X, Ehtesham M, Yin D, Black KL, **Yu JS**. Small interference RNA modulation of Interleukin 10 in human monocyte-derived dendritic cells enhances the Th1 response. *Eur J Immunology* 34(6):1680-87, 2004
33. Ehtesham E, Kabos P, Chung NHC, Liu G, Akasaki Y, Black KL, **Yu JS**. Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. *Neoplasia* 6:287-293, 2004.
34. Kabos P, Matundan H, Zandian M, Bertolotto C, Robinson M, Davy BE, **Yu JS**, Krueger RC Jr. Neural Precursors express multiple chondroitin sulfate proteoglycans, including the lectican family. *Biochem Biophys Res Commun* 318:955-63, 2004.
35. Liu G, **Yu JS**, Zeng G, Yin D, Xie D, Black KL, Ying H. AIM-2: A Novel Tumor Antigen Is Expressed and Presented by Human Glioma Cells. *J Immunotherapy* 27:220-6, 2004.
36. **Yu JS**, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen specific cytotoxic T cells in patients with malignant glioma. *Cancer Res* 64:4973-9, 2004.
37. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, **Yu JS**. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. *Cancer Res* 64:4980-4986, 2004.
38. Wheeler CJ, Das A, Liu G, **Yu JS**, Black KB. Clinical responsiveness of glioblastoma to chemotherapy after vaccination. *Clinical Cancer Res* 10(16):5316-26, 2004.
39. Wheeler CJ, **Yu JS**, Black KL. Cellular Immunity in the Treatment of Brain Tumors. *Clinical Neurosurgery* 51:132-139, 2004.
40. Akasaki C, Liu G, Chung NH, Ehtesham M, Black KL, **Yu JS**. Induction of a CD4<sup>+</sup> T regulatory type-1 response by cyclooxygenase-2 overexpressing glioma. *J Immunology* 173(7):4352-9, 2004.
41. Yuan X, Curtin J, Xiong Y, Liu G, Waschmann-Hogiu S, Farkas DL, Black KL, **Yu JS**, Isolation of cancer stem Cells from adult glioblastoma multiforme. *Oncogene* 23(58):9392-400, 2004.
42. Akasaki Y, Black KL, **Yu JS**. Dendritic cell-based immunotherapy for malignant gliomas. *Exp Rev Neurotherapeutics* 5(4):497-508, 2005.
43. Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, **Yu JS**. Cytotoxic T cell targeting of TRP-2 Sensitizes human malignant glioma to chemotherapy. *Oncogene* 24(33):5226-5234, 2005.
44. Akasaki Y, Black KL, **Yu JS**. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches. *Front Biosci* 10:2908-2921, 2005.
45. **Yu JS**, Vilhauer J. Quality of life for patients with glioblastoma. *Lancet Oncol* 6(12):913-4, 2005.
46. Irvin DM, Yuan X, Zeng Z, Tunici P, **Yu JS**. Neural Stem Cells – A Promising Potential Therapy for Brain Tumors. *Current Stem Cell Res & Ther*, 1:79-84, 2006.
47. Krueger RC Jr, Wu H, Zandian M, Danielpour M, Kabos P, **Yu JS**, Sun Ye. Neural progenitors populate the cerebrospinal fluid of preterm patients with hydrocephalus. *J of Pediatrics*. 148(3):337-340, 2006.
48. Yuan X, Hu J, Belladonna M, Black KL, **Yu JS**. IL-23 expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. *Cancer Res* 66(5):2630-8, 2006.

49. Akasaki Y, Liu G, Matundan HH, Ng H, Yuan X, Zeng Z, Black KL, **Yu JS**. A peroxisome proliferator-activated receptor-gamma (PPARgamma ) agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein tyrosine phosphatase-1B on human glioma cells. *J Biol Chem*. 281(10):6165-6174, 2006.
50. Liu G, Black KL, **Yu JS**. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. *Exp Rev of Vaccines* 5(2):233-247, 2006.
51. Tunic P, Irvin DM, Liu G, Yuan X, Zeng Z, Ng H, **Yu JS**. Brain Tumor Stem Cells: New Targets for Clinical Treatments? *Neurosurg Focus* 20(4):E27, 2006.
52. Candolfi M, Jaita G, Pisera D, Ferrari L, Barcia C, Liu C, **Yu JS**, Liu G, Castro MG, Seilicovich A. Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells. *J of Endocrinology* 189:681-690, 2006.
53. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, **Yu JS**. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. *Cancer Res*. 66(17): 8887-96, 2006.
54. Liu G, Yuan X, Zeng Z, Tunic P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, **Yu JS**. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. *Mol Cancer*. 5:67, 2006.
55. **Yu JS**, Luptrawan A, Black KL, Liu G. Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination. *Clin Neurosurg* 53:345-51, 2006.
56. Yu JJ, Sun X, Yuan X, Lee JW, Snyder EY, **Yu JS**. Immunomodulatory neural stem cells for brain tumor therapy. *Exp Op Biol Ther* 6 (12):1255-1262, 2006.
57. Zeng Z, Liu G, Yuan X, Zeng Xianhao, Zeng Xiaorong, Ng H, Chen H, Jiang T, Akasaki Y, Kessey K, Black KL, **Yu JS**. Manipulation of proliferation and differentiation of human bone marrow derived neural stem cells in vitro and in vivo. *J of Neurosci Res* 85(2):310-20, 2007.
58. Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunic P, Konda B, Wachsmann-Hogiu S, Black KL, **Yu JS**. Spheres Isolated from 9L Gliosarcoma Rat Cell Line Possess Chemoresistant and Aggressive Cancer Stem-Like Cells. *Stem Cells* 2:1645-53, 2007.
59. Liu G, **Yu JS**. Cancer vaccines: A novel strategy to sensitize malignant glioma to chemotherapy. *Expert Rev Neurother* 10:1235-7, 2007.
60. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang X, Pepkowitz S, Goldfinger D, Ng H, Irvin D, **Yu JS**. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. *Cancer Res* 68(14):5955-64, 2008.
61. Xu Q, Yuan X, Liu G, Black KL, **Yu JS**. Hedgehog signaling regulates brain tumor stem cell self-renewal and portends a shorter survival for patients with PTEN-coexpressing glioblastomas. *Stem Cells* 26(12):3018-26, 2008.
62. Lee BS, Yuan X, Xu Q, McLafferty FS, Petersen BA, Collette JC, Black KL, **Yu JS**: Preparation and characterization of antioxidant nanospheres from multiple alpha-lipoic acid-containing compounds.. *Bioorg Med Chem Lett*. 19(6):1678-81, 2009.
63. Lee BS, Yuan X, Xu Q, McLafferty FS, Petersen BA, Collette JC, Black KL, **Yu JS**: Stimuli-responsive antioxidant nanoprodrugs of NSAIDs. *Int J Pharm*. 372(1-2):112-24, 2009.
64. Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, **Yu JS**. Antigen-Specific T Cell Response from Dendritic Cell Vaccination Using Cancer Stem-like Cell-Associated Antigens. *Stem Cells*. 27(8):1734-40, 2009.
65. Xu Q, Yuan X, Tunic P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, **Yu JS**: Isolation of tumour stem-like cells from benign tumours, *Br J Cancer* 101(2):303-11, 2009

66. Tunici P, **Yu JS**. Pituitary adenoma stem cells. *Methods Mol Biol.* 568:195-201, 2009.
67. Xu Q, Yuan X, Xu M, McLafferty F, Hu J, Lee BS, Liu G, Zeng Z, Black KL, **Yu JS**: Chemokine CXC receptor 4--mediated glioma tumor tracking by bone marrow--derived neural progenitor/stem cells. *Mol Cancer Ther* 8(9):2746-53, 2009.
68. Lee BS, Yuan X, Xu Q, Ko M, Nalla A, Frankiel I, Shear T, Black KL, **Yu JS**: Nanoprodugs of NSAIDs inhibit the growth of U87-MG glioma cells. *J Nanomaterials*, 2010.
69. Lee BS, Nalla A, Stock IR, Shear TC, Black KL, **Yu JS**: Oxidative stimuli-responsive nanoprodug of camptothecin kills glioblastoma cells. *Bioorg Medi Chem Lett* 1;20(17):5262-8, 2010.
70. Li Z, Lee JW, Mukherjee D, Ji J, Jeswani SP, Black KL, **Yu JS**: Immunotherapy targeting glioma stem cells - insights and perspectives. *Expert Opin Biol Ther.* 2011 Dec 26. [Epub ahead of print].
71. Milanesi A, Lee JW, Xu Q, Perin L, **Yu JS**: Differentiation of nestin-positive cells derived from bone marrow into pancreatic endocrine and ductal cells in vitro. *J Endocrinol.* 209(2):193-201, 2011.
72. Lee BS, Yoon CW, Osipov A, Moghavem N, Nwachokor D, Amatya R, Na R, Pantoja JL, Pham MD, Black KL, **Yu JS**: Nanoprodugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodugs. *J Drug Deliv.* 2011:980720.
73. Carico C, Nuño M, Mukherjee D, Elramsisy A, Dantis J, Hu J, Rudnick J, **Yu JS**, Black KL, Bannykh SI, Patil CG: Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients. *PLoS ONE*, 7(3):e33684, 2012.
74. Nuño M, Mukherjee D, Elramsisy A, Nosova K, Lad SP, Boakye M, **Yu JS**, Black KL, Patil CG: Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases. *Annals Surg Oncol*, 9(8):2657-63, 2012.
75. Xu Q, Yuan X, **Yu JS**: Glioma stem cell research for the development of immunotherapy. *Adv Exp Med Biol.* 746:216-25, 2012.
76. Milanesi A, Lee JW, Li Z, Da Sacco S, Villani V, Perin L, **Yu JS**.  $\beta$ -cell Regeneration Mediated by Human Bone Marrow Mesenchymal Stem Cells. *PLoS ONE*,7(8):e42177, 2012.
77. Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, **Yu JS**, Bannykh SI, Black KL, M Nuño: Prognosis of Patients with Multifocal Glioblastoma: A Case-Controlled Study. *Journal of Neurosurgery*, 117(4):705-11, 2012.
78. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang HQ, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JM, Hawkins ES, Patil CG, Black KL, **Yu JS**. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. *Cancer Immunol Immunother* 62(1):125-35, 2013.
79. Patil CG, Nuño M, Elramsisy A, Mukherjee D, Carico C, Dantis J, Hu J, **Yu JS**, Fan X, Black KL, Bannykh SI: High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. *Neuro Oncol.* 15(1):104-11, 2013.
80. Lee BS, Amano T, Wang HQ, Pantoja JL, Yoon CW, Hanson CJ, Amatya R, Yen A, Black KL, **Yu JS**: Reactive oxygen species responsive nanoprodug to treat intracranial glioblastoma. *ACS Nano* 23;7(4):3061-77, 2013.
81. Clond MA, Lee BS, Yu JJ, Singer MB, Amano T, Lamb AW, Drazin D, Kateb B, Ley EJ, **Yu JS**: Reactive oxygen species-activated nanoprodug of Ibuprofen for targeting traumatic brain injury in mice. *PLoS One.* 8(4):e61819, 2013.
82. Ji J, Judkowski VA, Liu G, Wang H, Bunying A, Li Z, Xu M, Bender J, Pinilla C, **Yu JS**: Identification of novel HLA-A\*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy. *Stem Cells Trans Med.* 3(3): 356-364, 2014.

83. Kicielinski KP, Chiocca EA, **Yu JS**, Gill GM, Coffey M, Markert JM: Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. *Mol Ther.* 22(5):1056-62, 2014.
84. Santos R, Buying A, Sabri N, **Yu JS**, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA. Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. *Cells.* 4(1):1-18, 2014.
85. Wu JB, Shi C, Chu GC, Xu Q, Zhang Y, Li Q, **Yu JS**, Zhau HE, Chung LW. Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor. *Biomaterials* 67:1-10, 2015
86. Madany M, Thomas TM, Edwards L, **Yu JS**: Immunobiology and immunotherapeutic targeting of glioma stem cells. *Adv Exp Med Biol.*;853:139-66, 2015.
87. Thomas TM, **Yu JS**: Metabolic Regulation of Glioma Stem-like Cells in the Tumor Micro-environment. *Cancer Letters.* 2017 Jul 22. pii: S0304-3835(17)30449-4. PMID: 28743531
88. Edwards LA, Li A, Berel D, Madany M, Kim NH, Liu M, Hymowitz M, Uy B, Jung R, Xu M, Black KL, Rentsendorj A, Fan X, Zhang W, **Yu JS**. ZEB1 regulates glioma stemness through LIF repression. *Sci Rep.* 2017 Dec;7(1):69
89. Thomas TM, **Yu JS**. Metabolic Regulation of Glioma Stem-Like Cells in the Tumor Micro-Environment. *Cancer Lett.* 2017 Nov 1;408:174-181. doi: 10.1016/j.canlet.2017.07.014. Epub 2017 Jul 22. Review. PMID: 2874531
90. Chang FC, Levengood, SL, Cho N, Chen L, Wang E, **Yu JS**, Zhang M. Crosslinked Chitosan-PEG Hydrogel for Culture of Human Glioblastoma Cell Spheroids and Drug Screening. *Advanced Therapeutics*, In press. 2018
91. Michael J, Lee, BS Zhang M, **Yu JS**. Nanotechnology for treatment of Glioblastoma Multiforme. *Journal of Translational Medicine.* In press 2018

## Chapters

1. **Yu JS**, Harsh GR, IV, Breakefield XO. Chapter 3: Basic concepts of gene therapy. The Molecular Basis of Neurosurgical Disease Volume 8: Concepts in Neurosurgery, Raffel C, Harsh GR, IV, Eds. Baltimore, MD: Williams and Wilkins, 1996.
2. Ojemann RG and **Yu JS**. Anterior fossa tuberculum sella and olfactory groove meningiomas. Skull Base Surgery: Management, Complications and Outcomes. Robertson JT, Coakham H, Eds. New York, NY: Churchill Livingstone, 1998.
3. **Yu JS**, Carter BS, Harsh GR, IV. Gene therapy for metastases and carcinomatous meningitis. In Advanced Techniques in Central Nervous System Metastases, Neurological Topics Series, American Association of Neurological Surgeons, Maciunas RJ, Ed. Baltimore, MD: Williams and Wilkins, 1998.
4. **Yu JS**, Ehtesham M, Black KB. Chapter 15: Immunotherapy for Malignant Gliomas. Cancer of the Nervous System 2<sup>nd</sup> Edition Black PM, Loeffler JS, Eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
5. **Yu JS**, Luptrawan A, Wallace RE, Hakimian B. Chapter 15: Radiosurgery of Intracranial Lesions. Neurosurgical Operative Atlas Badie B, Ed. , 2006.
6. **Yu JS**, Luptrawan A, Liu G: Dendritic Cell Immunotherapy for Malignant Gliomas. Rev Recent Clin Trials. 3(1):10-21, 2008.
7. Xu Q, Yuan X, **Yu JS**. Glioma Stem Cell Research for the Development of Immunotherapy. Glioma: Immunotherapeutic Approaches. Yamanaka R, Ed., Landes Bioscience, 2009.
8. Liu G, **Yu JS**. Targeting Brain Tumor Stem Cells in the Clinic. Stem Cells and Cancer. Bagley RG & Teicher BA, Eds., Humana Press, 2009.
9. **Yu, JS**: Cancer Stem Cell Techniques, Volumes in Molecular Biology Series, *Humana Press*, 2009.
10. Ji J, Black KL, **Yu JS**. Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am. Yang I & Lim M, Eds. Saunders,1:159-166 2010.

11. Hu J, Yuan X, Xu Q, **Yu JS**. Isolation of Cancer Stem Cells from Glioblastoma. Tumors of the Central Nervous System Hayat MA, Ed, 2010.
12. Xu Q, Yuan X, **Yu JS**. Glioma stem cell research for the development of immunotherapy. Glioma Immunotherapeutic Approaches, Yamanaka R, ed. Springer, 2011.
13. Li Z, Mukherjee D, Lee J, **Yu JS**. Molecular targeting of cancer stem cells, Cancer Vaccines, Second Ed., Bot, Marincola, Obrocea, Eds., Springer, 2011.
14. Lee, B, **Yu, JS**. Nanoprodug therapy for glioblastoma. Nanosurgery, Kateb, B., ed. Taylor & Francis, 2011.
15. Lee B, Hanson CJ, Amatya R, Chung E, Ghani M, Yen A, Black KL, **Yu JS**. Nanoparticle-Based Treatment and Imaging of Brain Tumors: Potentials and Limitations. The Textbook of Nanoneuroscience and Nanoneurosurgery, Kateb B and Heiss JD, Eds., CRC Press, 2013.
16. Madany M, Thomas TM, Edwards L, **Yu JS**. Immunobiology and Immunotherapeutic Targeting of Glioma Stem Cells. Stem Cell Biology in Neoplasms of the Central Nervous System. Ehtesham M, Ed., Springer, 2015

#### Reviews

1. *Glioblastoma Multiforme* by Dr. James Markert in Neuro-Oncology 2005 Volume 7, issue 2. Published 11 February 2005.
2. *Progress in Experimental Tumor Research, Vol. 39: "Neuronal Activity in Tumor Tissue"* edited by Kurt.S. Zänker and Frank Entschladen for Journal of Neurosurgery.
3. *High-Grade Gliomas: Diagnosis and Treatment* edited by Gene H. Barnett for Journal of Neurosurgery.

#### Abstracts

1. **Yu JS**, Samoto K, Liu Y, Lee O, Wechsler S, Nesburn , Black KL : A novel herpes simplex rec ombinant virus for the treatment of gliomas. Academy of Neurological Surgeons, Nov. 3, 1998, Santa Barbara, California
2. **Yu JS**, Wheeler CJ , Zeltzer PM., Nacis-Finger D, Lee PK , Prins R , Yong W, Thompson RC , Riedinger M , Zhang W, and Black KL: Fast expression in tumor vessels of patients with glioblastoma multiforme. Academy of Neurological Surgeons, Nov. 12, 1999., Amelia Island, Florida
3. **Yu JS**, Liu Y,Zhang H, Wheeler C, Samoto K, Liu C, Villareal L, Black KL :Intracranial adenoviral interleukin 12 delivery effects potent and long-lasting immunity against glioma. Congress of Neurological Surgeons, October 1999 Boston, Massachusetts
4. Wheeler C, Prins R, Lee P, Liu Y, Sugita M, Thompson RC, **Yu JS** , Black KL :Local and systemic alteration of cellular immune components in experimental glioma. American Association of Neurological Surgeons, October 1999 New Orleans
5. **Yu JS**, Samoto K, Liu Y, Lee O, Wechsler S, Nesburn A, Black KL:A novel herpes simplex virus mutant is safe and human glioma specific. American Association of Neurological Surgeons, April 1999 New Orleans
6. Black KL, Zeltzer PM, Wheeler CJ, R Trauger, Bartholemew R, Thefan G, Ying H, Yong W, Lee P, **Yu JS**: Dendritic cell immunotherapy for malignant glioma. Neurosurgical Society of America, June 4, 2000, Durango, Colorado
7. **Yu JS**, Ehtesham M, Samoto K, Wheeler CJ, and Black KL: Endothelial Fast expression inhibits a cytotoxic T cell reponse in glioblastoma. Neurosurgical Society of America , June 4, 2000, Durango, Colorado
8. **Yu JS**, Zeltzer PM, Wheeler CJ, Trauger R, Bartholemew R, Thefan G, Ying H, Yong W, Lee P , Black KL :Dendritic cell immunotherapy for gliomas. Academy of Neurological Surgeons, Oct. 13, 2000, Colorado Springs, Colorado
9. Samoto K , Ehtesham M, (Los Angeles, CA), Black KL, and **Yu JS**. TNF-alpha and IFN-gamma gene therapy for brain tumors. Evidence for a strong synergy leading to apoptosis in

- endothelial and neoplastic cells. Congress of Neurological Surgeons, October 2000 San Antonio, Texas
10. **Yu JS**, Wheeler CJ, Zeltzer PM , Nacis-Finger D, Lee PK , Prins R, Yong W , Thompson RC, Riedinger M , Zhang W, and Black KL : Vaccination of recurrent malignant glioma patients with tumor-lysate pulsed dendritic cells elicits a potent T-cell anti-tumor. Congress of Neurological Surgeons, October 2000 San Antonio, Texas
  11. **Yu JS**, Ehtesham M, Samoto K, Wheeler CJ, and Black KL: Expression of Fas Ligand on brain tumor endothelium. Implications for immune escape. Congress of Neurological Surgeons, October 2000 San Antonio, Texas
  12. Black KL, Wheeler CJ, Zeltzer PM, Nacis-Finger D, Lee PK, Prins R, Yong WH , Thompson RC, Riedinger M, Zhang W, and **Yu JS**: Dendritic cell vaccination of patients with malignant glioma elicits systemic and intracranial T-cell response. Congress of Neurological Surgeons, October 2000 San Antonio, Texas
  13. **Yu JS**, Wheeler CJ, Zeltzer PM, Lee PK, Yong WH, Riedinger MS, Black KL: Dendritic Cell Immunotherapy for Patients with Glioblastoma and Anaplastic Astrocytoma. American Society for Clinical Oncology Annual Meeting: May 12-15, 2001, San Francisco, California
  14. **Yu JS**, Zeltzer PM, Wheeler CJ, Trauger R, Bartholemew R, Thefan G, Ying H, Yong W, Lee P, Black KL: Active immunotherapy for gliomas. Western Neurosurgical Society, September 21, 2001, Kona, HI
  15. **Yu JS**, Zeltzer PM, Wheeler CJ, Trauger R, Bartholemew R, Thefan G, Ying H, Yong W, Lee P, Black KL: Mechanisms of immunoevasion by gliomas. Academy of Neurological Surgeons, October 28, 2001, Williamsburg, Virginia
  16. Ehtesham M, Kabos P, Gutierrez M, Clay A, Neuman T, Black KL, and **Yu JS**. Congress of Neurological Surgeons, October 2001 San Diego, California
  17. **Yu JS**, Zeltzer PM, Wheeler CJ, Trauger R, Bartholemew R, Thefan G, Ying H, Yong W, Lee P, Black KL: Vaccination with GM-CSF secreting cells and dendritic cells induce intracranial cytotoxic T cell responses. Congress of Neurological Surgeons, October 2001 San Diego, California
  18. **Yu JS**, Ehtesham M, Samoto K, Black KL: The use of LacZ engineered dendritic cells for brain tumor immunotherapy. American Association of Neurological Surgeons, April 2001 Toronto, Canada
  19. **Yu JS**, Ehtesham M, Samoto K, Black KL: Expression of Fas Ligand on brain tumor endothelium: Implications for immune escape. American Association of Neurological Surgeons, April 2001 Toronto, Canada
  20. **Yu JS**, Ken Samoto, MD PhD, Moneeb Ehtesham, MD, Keith L. Black, MD: Interleukin-12, TNF alpha, and IFN gamma gene transfer for gliomas induces intratumoral T cell infiltration. American Association of Neurological Surgeons, April 2001 Toronto, Canada
  21. Ehtesham M, Kabos P Gutierrez M, Chung N, Black KL, **Yu JS**: The Use of TRAIL Gene Therapy for the Induction of Apoptosis in Malignant Brain Tumors. Congress of Neurological Surgeons, October 2002, Philadelphia, Pennsylvania
  22. Ehtesham M, Kabos P, Gutierrez MAR, Samoto K , Black KL, **Yu JS**: Treatment of Intracranial Brain Tumors Using in situ Dendritic Cell Vaccination. Congress of Neurological Surgeons, October 2002, Philadelphia, Pennsylvania
  23. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, **Yu JS**: The Use of Interleukin 12-secreting Neural Stem Cells for the Treatment of Intracranial Glioma. Congress of Neurological Surgeons, October 2002, Philadelphia, Pennsylvania
  24. Liu G, Ying H, Zeng G, Dudley ME, Wheeler CJ, Black KL, **Yu JS**: Evaluation of HER-2, gp100 and MAGE-1 as Tumor Antigens for GBM Immunotherapy. Congress of Neurological Surgeons, October 2003, Denver, Colorado
  25. **Yu JS**; Black KL, Liu G, Wheeler CJ, Wagenberg M, Das A, Mindlin E, Chu RM, Luptrawan A, Badruddoja MA: Results of a Phase II Trial of Tumor Lysate-pulsed Dendritic

- Cell Vaccination for Malignant Glioma. Congress of Neurological Surgeons, October 2005, Boston, Massachusetts
26. **Yu JS**; Liu G, Morris-Irvin D, Black KL : Glioblastoma Cancer Stem Cells Exhibit Chemoresistance with Overexpression of Multi-drug Resistance Gene BCRP-1. Congress of Neurological Surgeons, October 2005, Boston, Massachusetts
  27. **Yu JS**; Yuan X, Liu G, Zeng Z, Morris-Irvin D, Black KL: IL-23-expressing Bone Marrow-derived Neural Stem-like Cells Exhibit Antitumor Activity against Intracranial Glioma. Congress of Neurological Surgeons, October 2005, Boston, Massachusetts
  28. Akasaki Y, Black KL, **Yu JS**: Role of PTP1B in STAT3 Signaling for Facilitation of Caspase Cascade on Human Glioma Cells. Congress of Neurological Surgeons, October 2005, Boston, Massachusetts
  29. **Yu JS**; Liu G, Ng H, Wagenberg M, Luptrawan A, Mindlin E, Wheeler CJ, Black KL : A Phase I Trial of Intracranial Dendritic Cell Immunotherapy for Patients with Malignant Glioma. Congress of Neurological Surgeons, October 2006, Chicago, Illinois
  30. Ghods AJ, Black KL, **Yu JS**: Spheres Isolated from the 9L Gliosarcoma Rat Cell Line Possess Cancer Stem-Like Cells. Congress of Neurological Surgeons, October 2006, Chicago, Illinois
  31. **Yu JS**, Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL: Induction of potent antitumor immunity by intratumoral injection of IL-23 transduced dendritic cells. Fifth Biennial Meeting of the Immunotherapy Task Force, Joint Section on Tumors, (AANS and CNS), Nov. 16, 2006, Orlando, Florida
  32. **Yu JS**, Liu G, Ng H, Wagenberg M, Luptrawan A, Mindlin E, Wheeler CJ, Black, KL: Intratumoral dendritic cell immunotherapy induces systemic cytotoxicity. Society for Neuro-Oncology, Nov. 2006, Orlando, Florida.
  33. **Yu JS**, Liu G; Morris-Irvin D, Black KL: Glioblastoma Cancer Stem Cells Exhibit Chemoresistance with BCRP-1 Overexpression. Society for Neuro-Oncology, Nov. 2006, Orlando, Florida.
  34. Yu JS, Liu G, Zheng Z , Ng H , Abdulkadir R, Lu L , Black, KL: Functional TLR-9 expression, regulation, and clinical significance in GBM patients. Proceedings of the American Association for Cancer Research, 98th Annual Meeting, April 18, 2007, Los Angeles, CA.
  35. **Yu JS**, Xu Q , Yuan X , Liu G, Black KL , Hedgehog signaling regulates brain tumor stem cell self-renewal. International Society for Stem Cell Research, June 13, 2008, Philadelphia, PA.
  36. **Yu JS**, Xu Q, Yuan X, Liu G, Black KL: Identification of a Human Pituitary Adenoma Stem Cell. Congress of Neurological Surgeons, September 22, 2008, Orlando, FL.
  37. **Yu JS**, Q Xu, Yuan X, Liu G, Black KL, Hedgehog signaling regulates brain tumor stem cell self-renewal and portends a shorter survival for patients with PTEN-coexpressing glioblastomas. Congress of Neurological Surgeons, September 22, 2008, Orlando, FL.
  38. **Yu JS** , Liu G, Mazer M, Black KL, CD133 as a potential target of anti-cancer stem cell immunotherapy: Identification of a HLA-A\*02 restricted CD133 epitope. International Society for the Biological Therapy of Cancer, November 2, 2008, San Diego, CA.
  39. Phuphanich S, Rudnick J, Wagenberg M, Luptrawan A, Mindlin E, Wheeler CJ , Black KL, Singh M, **Yu JS**: A phase I trial of tumor associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma. American Society for Clinical Oncology; June 1, 2009, Orlando, Florida.
  40. Rudnick J, Phuphanich S, Wagenberg M, Luptrawan A, Chu RM, Wheeler CJ, Black KL, **Yu JS** : A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. American Society for Clinical Oncology; June 1, 2009, Orlando, Florida.



41. **Yu JS**; Liu G; Ng H; Wagenberg M; Luptrawan A; Mindlin E, Wheeler CJ, Black KL. A Phase I Trial of Intracranial Dendritic Cell Immunotherapy for Patients with Malignant Glioma. International Society for Radiosurgery; June 5, 2009, Seoul, Korea
42. **Yu JS**, Phuphanich S, Wagenberg M, Luptrawan A, Chu RM, Wheeler CJ, Black KL, Rudnick J: A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. American Association of Neurological Surgeons; May 3, 2010, Philadelphia, PA.
43. Phuphanich S, Rudnick J, Wagenberg M, Luptrawan A, Mindlin E, Wheeler CJ, Black KL, Singh M, **Yu JS**: Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107). American Society for Clinical Oncology; June 5, 2010, Chicago, IL.
44. **Yu JS**, Phuphanich S, Wagenberg M, Luptrawan A, Chu RM, Wheeler CJ, Black KL, Rudnick J: A cancer vaccine targeting cancer stem cell antigens (ICT-107) demonstrates correlated tumor antigen expression and progression free survival and may reduce the cancer stem cell population in recurrent tumors. Society for Neuro-Oncology, Nov. 18, 2011, Anaheim, CA.
45. Hu, J, Phuphanich S, Rudnick J, Wagenberg M, Luptrawan A, Mindlin E, Wheeler CJ, Black KL, Singh M, **Yu JS**. Dendritic cell vaccine therapy for patients with recurrent glioblastoma: A single institution pooled analysis of four trials. Society for Neuro-Oncology, Nov. 18, 2011, Anaheim, CA.
46. P.Y. Wen, D.A. Reardon, S. Phuphanich, R. Aiken, J.C. Pandolfi, W.T. Curry, J.J. Zhu, M.J., Glantz, D.M. Peereboom, J. Markert, R.V. LaRocca, D. O'Rourke, K.L. Fink, L.J. Kim, M.O. Gruber, G.J. Lesser, E. Pan, S. Kesari, **J.S. Yu**. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. American Society for Clinical Oncology, June 1, 2014, Chicago, IL.
47. Wen, D.A. Reardon, S. Phuphanich, R. Aiken, J.C. Pandolfi, W.T. Curry, J.J. Zhu, M.J., Glantz, D.M. Peereboom, J. Markert, R.V. LaRocca, D. O'Rourke, K.L. Fink, L.J. Kim, M.O. Gruber, G.J. Lesser, E. Pan, S. Kesari, **J.S. Yu**. A randomized double blind placebo-controlled phase 2 trial of dendritic cell (DC) vaccine ICT-107 following standard treatment in newly diagnosed patients with GBM. Society for Neuro-Oncology Nov. 14, 2014, Miami, FL.
48. T.S. Armstrong, P.Y. Wen, D.A. Reardon, S. Phuphanich, R. Aiken, J.C. Pandolfi, W.T. Curry, J.J. Zhu, M.J., Glantz, D.M. Peereboom, J. Markert, R.V. LaRocca, D. O'Rourke, K.L. Fink, L.J. Kim, M.O. Gruber, G.J. Lesser, E. Pan, S. Kesari, **J.S. Yu**. Comparative Impact of Treatment on Clinical Benefit in Patients with glioblastoma (GBM) Enrolled in the Phase II Trial of ICT-107. American Society for Clinical Oncology, May 30, 2015, Chicago, IL.
49. **Yu J.S.**, P. Wen, D.A. Reardon, S. Phuphanich, R. Aiken, J.C. Pandolfi, W.T. Curry, J.J. Zhu, M.J., Glantz, D.M. Peereboom, J. Markert, R.V. LaRocca, D. O'Rourke, K.L. Fink, L.J. Kim, M.O. Gruber, G.J. Lesser, E. Pan, S. Kesari. Association of survival and progression-free survival with immune response in HLA-A2+ newly-diagnosed GBM patients in randomized double-blind placebo-controlled phase 2 trial of dendritic cell (DC) immunotherapy with ICT-107. Society for Neuro-Oncology, Nov. 20, 2015, San Antonio, TX.
50. Chiocca E.A., **Yu J.S.**, Lucas R.V., Reardon D.A., Wen P., Stopa B., Naik A., Buck J.Y., Demars N., Barrett J.A., Gelb A., Zhou J., Cooper L.J.N., Lebel F. Controlled IL-12 adenoviral gene therapy in the treatment of high grade gliomas. Society for Neuro-Oncology, Nov. 19, 2017, San Francisco, CA.